Literature DB >> 35522427

Ongoing Challenges in the Diagnosis of 11p15.5-Associated Imprinting Disorders.

Deborah J G Mackay1,2, I Karen Temple3,4.   

Abstract

The overgrowth disorder Beckwith-Wiedemann syndrome and the growth restriction disorder Silver-Russell syndrome have been described as 'mirror' syndromes, in both their clinical features and molecular causes. Clinically, their nonspecific features, focused around continuous variables of atypical growth, make it hard to set diagnostic thresholds that are pragmatic without potentially excluding some cases. Molecularly, both are imprinting disorders, classically associated with 'opposite' genetic and epigenetic changes to genes on chromosome 11p15, but both are associated with somatic mosaicism as well as an increasing range of alternative (epi)genetic changes to other genes, which make molecular diagnosis an increasingly complex process. In this Current Opinion, we explore how the understanding of Beckwith-Wiedemann syndrome and Silver-Russell syndrome has evolved in recent years, stretching the canonical 'mirror' designations in different ways for the two disorders and how this is changing clinical and molecular diagnosis. We suggest some possible directions of travel toward more timely and stratified diagnosis, so that patients can access the early interventions that are so critical for good outcome.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2022        PMID: 35522427     DOI: 10.1007/s40291-022-00587-1

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  55 in total

1.  Diagnosis and management of Silver-Russell syndrome: first international consensus statement.

Authors:  Emma L Wakeling; Frédéric Brioude; Oluwakemi Lokulo-Sodipe; Susan M O'Connell; Jennifer Salem; Jet Bliek; Ana P M Canton; Krystyna H Chrzanowska; Justin H Davies; Renuka P Dias; Béatrice Dubern; Miriam Elbracht; Eloise Giabicani; Adda Grimberg; Karen Grønskov; Anita C S Hokken-Koelega; Alexander A Jorge; Masayo Kagami; Agnes Linglart; Mohamad Maghnie; Klaus Mohnike; David Monk; Gudrun E Moore; Philip G Murray; Tsutomu Ogata; Isabelle Oliver Petit; Silvia Russo; Edith Said; Meropi Toumba; Zeynep Tümer; Gerhard Binder; Thomas Eggermann; Madeleine D Harbison; I Karen Temple; Deborah J G Mackay; Irène Netchine
Journal:  Nat Rev Endocrinol       Date:  2016-09-02       Impact factor: 43.330

2.  A retrospective analysis of the prevalence of imprinting disorders in Estonia from 1998 to 2016.

Authors:  Maria Yakoreva; Tiina Kahre; Riina Žordania; Karit Reinson; Rita Teek; Vallo Tillmann; Aleksandr Peet; Eve Õiglane-Shlik; Sander Pajusalu; Ülle Murumets; Mari-Anne Vals; Pille Mee; Monica H Wojcik; Katrin Õunap
Journal:  Eur J Hum Genet       Date:  2019-06-11       Impact factor: 4.246

3.  Mutations of the Imprinted CDKN1C Gene as a Cause of the Overgrowth Beckwith-Wiedemann Syndrome: Clinical Spectrum and Functional Characterization.

Authors:  Frederic Brioude; Irène Netchine; Francoise Praz; Marilyne Le Jule; Claire Calmel; Didier Lacombe; Patrick Edery; Martin Catala; Sylvie Odent; Bertrand Isidor; Stanislas Lyonnet; Sabine Sigaudy; Bruno Leheup; Séverine Audebert-Bellanger; Lydie Burglen; Fabienne Giuliano; Jean-Luc Alessandri; Valérie Cormier-Daire; Fanny Laffargue; Sophie Blesson; Isabelle Coupier; James Lespinasse; Patricia Blanchet; Odile Boute; Clarisse Baumann; Michel Polak; Berenice Doray; Alain Verloes; Géraldine Viot; Yves Le Bouc; Sylvie Rossignol
Journal:  Hum Mutat       Date:  2015-08-06       Impact factor: 4.878

4.  Analysis of the IGF2/H19 imprinting control region uncovers new genetic defects, including mutations of OCT-binding sequences, in patients with 11p15 fetal growth disorders.

Authors:  Julie Demars; Mansur Ennuri Shmela; Sylvie Rossignol; Jun Okabe; Irène Netchine; Salah Azzi; Sylvie Cabrol; Cédric Le Caignec; Albert David; Yves Le Bouc; Assam El-Osta; Christine Gicquel
Journal:  Hum Mol Genet       Date:  2009-12-09       Impact factor: 6.150

5.  Epigenotype-phenotype correlations in Silver-Russell syndrome.

Authors:  E L Wakeling; S Abu Amero; M Alders; J Bliek; E Forsythe; S Kumar; D H Lim; F MacDonald; D J Mackay; E R Maher; G E Moore; R L Poole; S M Price; T Tangeraas; C L S Turner; M M Van Haelst; C Willoughby; I K Temple; J M Cobben
Journal:  J Med Genet       Date:  2010-08-03       Impact factor: 6.318

6.  Genetic variants within the second intron of the KCNQ1 gene affect CTCF binding and confer a risk of Beckwith-Wiedemann syndrome upon maternal transmission.

Authors:  Julie Demars; Mansur Ennuri Shmela; Abdul Waheed Khan; Kai Syin Lee; Salah Azzi; Patrice Dehais; Irène Netchine; Sylvie Rossignol; Yves Le Bouc; Assam El-Osta; Christine Gicquel
Journal:  J Med Genet       Date:  2014-07-04       Impact factor: 6.318

7.  Uniparental disomy 7 in Silver-Russell syndrome and primordial growth retardation.

Authors:  D Kotzot; S Schmitt; F Bernasconi; W P Robinson; I W Lurie; H Ilyina; K Méhes; B C Hamel; B J Otten; M Hergersberg
Journal:  Hum Mol Genet       Date:  1995-04       Impact factor: 6.150

Review 8.  Genomic imprinting disorders: lessons on how genome, epigenome and environment interact.

Authors:  David Monk; Deborah J G Mackay; Thomas Eggermann; Eamonn R Maher; Andrea Riccio
Journal:  Nat Rev Genet       Date:  2019-04       Impact factor: 53.242

9.  A prospective study validating a clinical scoring system and demonstrating phenotypical-genotypical correlations in Silver-Russell syndrome.

Authors:  Salah Azzi; Jennifer Salem; Nathalie Thibaud; Sandra Chantot-Bastaraud; Eli Lieber; Irène Netchine; Madeleine D Harbison
Journal:  J Med Genet       Date:  2015-05-07       Impact factor: 6.318

10.  Need for a precise molecular diagnosis in Beckwith-Wiedemann and Silver-Russell syndrome: what has to be considered and why it is important.

Authors:  Thomas Eggermann; Johanna Brück; Cordula Knopp; György Fekete; Christian Kratz; Velibor Tasic; Ingo Kurth; Miriam Elbracht; Katja Eggermann; Matthias Begemann
Journal:  J Mol Med (Berl)       Date:  2020-08-24       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.